久久综合日本久久综合,亚洲成AV人片在线观看天堂无码,国产在线视频不卡一区二区,久久久久看免费高清特色大片

武漢佰樂博生物技術(shù)有限公司
   
     
您當(dāng)前的位置: 網(wǎng)站首頁 > 產(chǎn)品展廳 >試劑盒 >BioSim Tovetumab ELISA Kit(KDD16102)
BioSim Tovetumab ELISA Kit(KDD16102)
  • 品牌:AntibodySystem
  • 產(chǎn)地:France
  • 型號:96 assays
  • 貨號:KDD16102
  • 發(fā)布日期: 2022-07-25
  • 更新日期: 2024-10-23
產(chǎn)品詳請
產(chǎn)地 France
保存條件 2-8 ℃
品牌 AntibodySystem
貨號 KDD16102
用途 For Research Use Only.
檢測方法 Elisa
CAS編號
保質(zhì)期 1 year
適應(yīng)物種 Tovetumab
檢測限 0.156 ug /ml
數(shù)量 99999
包裝規(guī)格 96 assays
標(biāo)記物 Unconjugate
純度 95%%
樣本 Plasma, Serum
應(yīng)用 Elisa
是否進(jìn)口


Catalog No.

KDD16102

Stability and Storage

The stability of ELISA kit is determined by the loss rate of activity. The loss rate of this kit is less than 10% prior to the expiration date under appropriate storage condition.

Detection method

Colorimetric

Precision

CV<20%

Sample type

Plasma, Serum

Assay type

Quantitative

Sensitivity

0.156 μg/ml

Range

0.31-5 μg/mL

Recovery

80-120%

Specifications

Tovetumab

Alternative Names

MEDI-575, CAS: 1243266-04-7

Background

Tovetumab (MEDI-575) is a fully human IgG2κ monoclonal antibody that specifically binds to human platelet-derived growth factor receptor alpha (PDGFRα) and blocks receptor signal transduction by PDGF ligands. The affinity of tovetumab determined using surface plasmon resonance technology and flow cytometry demonstrated comparable binding affinity for human and monkey PDGFRα. In single and repeat-dose monkey pharmacokinetic-pharmacodynamic (PK-PD) studies, tovetumab administration resulted in dose-dependent elevation of circulating levels of PDGF-AA, a member of the PDGF ligand family, due to displacement of PDGF-AA from PDGFRα by tovetumab and subsequent blockade of PDGFRα-mediated PDGF-AA degradation. As such, PDGF-AA accumulation is an indirect measurement of receptor occupancy and is a novel PD biomarker for tovetumab. The nonlinear PK of tovetumab and dose-dependent increase in circulating PDGF-AA profiles were well described by a novel mechanistic model, in which tovetumab and PDGF-AA compete for the binding to PDGFRα.

Shipping

2-8 ℃

Note

For Research Use Only.


Aiming to develop the most reliable bioreagents, AntibodySystem SAS was founded in 2019 in France by a team of professionals from top industrial companies and research institutes. The collective scientific and technical experiences in our team have brought breaking throughs in multiple product developments, including recombinant antibodies, recombinant proteins, biosimilar, RUO ELISA kits and other related products. By working with talented researchers and technicians, AntibodySystem continues to upgrade product qualities and lower the overall cost, offering accountable and affordable solutions for biolabs all over the world. Since its establishment, AntibodySystem has built long term and stable collaborations with academia, pharmaceutical industry, biotech companies and research hospitals, supporting their R&D by AntibodySystem's bioreagents with excellent data accuracy and reproducibility.




AntibodySystem由具有30多年蛋白抗體開發(fā)經(jīng)驗的 創(chuàng)立于法國,專注于生命科學(xué)和生物制藥領(lǐng)域研究,總部位于法國斯特拉斯堡市。AntibodySystem自主開發(fā)了高效、高產(chǎn)的真核重組表達(dá)系統(tǒng),利用該系統(tǒng)生產(chǎn)了高質(zhì)量的重組蛋白、抗體產(chǎn)品。目前產(chǎn)品包括藥物靶點蛋白以及對照抗體藥物、Invivo功能性抗體、SAA系列流式抗體、PEG抗體、磷酸化抗體、抗小分子抗體、ADA抗體、PK&ADA ELISA試劑盒。


普健生物作為AntibodySystem在亞洲區(qū)授權(quán) ,致力于為廣大科研工作者提供 的產(chǎn)品服務(wù)。

如果您對我們的產(chǎn)品感興趣,請聯(lián)系027-65279366。

以上產(chǎn)品僅用于科研,產(chǎn)品信息以產(chǎn)品 為準(zhǔn)






聯(lián)系方式
手機(jī):18162686757
微信掃一掃
贵德县| 鲜城| 江油市| 增城市| 隆德县| 麻阳| 色达县| 麻阳| 察隅县| 正安县| 内江市| 五常市| 齐河县| 定襄县| 台中市| 汨罗市| 自治县| 达州市| 横山县| 澄城县| 惠来县| 余庆县| 闽清县| 南充市| 武城县| 丹江口市| 金堂县| 中江县| 昭通市| 祁连县| 巴林右旗| 崇礼县| 丹凤县| 黑水县| 洛川县| 当阳市| 微博| 澄城县| 巫山县| 宝丰县| 滁州市|